2nd Due Diligence for Life Sciences

On-Demand Content | Virtual Event

PURCHASE ON-DEMAND
DOWNLOAD BROCHURE
2nd Due Diligence for Life Sciences
There’s no question that the pharmaceutical industry has been hit the hardest by COVID-19 and the many business roadblocks that have come along with it. Challenges continually arise in the pharmaceutical and life science industries regarding virtual safety of IP and due diligence practices. With the ever-evolving digital health environment, compliance practices are more important than ever. Production of the COVID-19 vaccine has brought new partnerships and M&A opportunities from non-traditional entrants which is calling for faster maturation of IP due diligence practices. Additionally, COVID-19 has caused an increase in digital health practices that are reshaping the diligence landscape for the pharmaceutical and life science industries which has created new impacts on deal-making landscapes. Best practices and standardization of due diligence amongst life science professionals is critical for continued success and compliance.
The aim of this event is to provide attendees with valuable insights and actionable strategies from cross-functional business development teams on how to execute optimal due diligence to successfully manage alliances, licensing agreements, and M&A deals. This event serves as an educational platform for industry experts responsible for due diligence, R&D, search and evaluation, external innovation, legal/IP, portfolio management, alliance management, business development and licensing, and more and will feature leadership representation from biotechs, mid-sized and large pharmaceutical, medical device and diagnostics companies.

SPEAKER HIGHLIGHTS

Gwilym Attwell
Gwilym Attwell
Patent Attorney

FISH & RICHARDSON

Markus Decker
Markus Decker

Global Head Search &
Evaluation Oncology
SIMCERE PHARMACEUTICAL GROUP

Paul Fehlner
Paul Fehlner
Senior Vice President, Chief Legal Officer and Corporate Secretary

AXCELLA

Mehdi Ganjeizadeh, Ph.D., J.D.
Mehdi Ganjeizadeh, Ph.D., J.D.

Executive Director
and Head of Gene Therapy IP
SAREPTA THERAPEUTICS

Sabeena Ghazal
Sabeena Ghazal

Due Diligence Specialist and
Third Party Risk Management Champion
NOVARTIS

Samuel Gosselin
Samuel Gosselin
Head, Corporate Development

CARE EVERYWHERE GROUP

Scott Kamholz
Scott Kamholz
M.D./Ph.D. Patent Consultant and Former Administrative Patent Judge

INDEPENDENT CONSULTANT

Ravi Kiron
Ravi Kiron
Head of BioPharma External Innovation

EMD SERONO, INC.

David Korn
David Korn
Vice President of Intellectual Property and Law

PHRMA

Stephan Kutik
Stephan Kutik

IP Lead for Nephrology
and Orphan Drugs
VIFOR PHARMA

Christopher Mortko
Christopher Mortko

Associate Vice President
and Head of Search and Evaluation
in Business Development
and Licensing
MERCK

Ahmed Mousa
Ahmed Mousa

Chief Business Officer
General Counsel
PIERIS PHARMACEUTICALS

Dr. Segev Shani
Dr. Segev Shani

Vice President, Medical &
Regulatory Affairs
NEOPHARM GROUP COMPANIES

Scott Simmons
Scott Simmons

Advisor, External Innovation –
Due Diligence
ELI LILLY

Steven Walker
Steven Walker
Director of Alliance management and M&A Integration

ELI LILLY

Lindsey Wanner
Lindsey Wanner

Senior Counsel, IP Alliance
and Due Diligence
GILEAD

VIEW ALL SPEAKERS

Who Should Purchase

Pharmaceutical, Biotechnology professionals whose responsibilities include:

  • Due Diligence
  • Business Development
  • Strategic Alliance/Alliance Management
  • Mergers and Acquisitions
  • Licensing
  • BD&L
  • General Counsel/Corporate Counsel
  • Legal and Regulatory Compliance
  • Legal / IP
  • Digital Partnerships
  • Digital Investments
  • Strategic Alliances/Partnerships
  • Management
  • Intellectual Property and Patent Counsel
  • Key Accounts/Key Account Management (KAM)
  • Search and Evaluation
  • Safety
  • Portfolio Management
  • Portfolio / Life Cycle Management
  • Search and Evaluation
  • External Innovation
  • Clinical Operations
  • Regulatory Affairs
  • Compliance
  • Scientific Assessment
  • Transactions

Secondary Market

  • Investment Banks
  • Private Equity Firms
  • Venture Capitalists
  • Data Room Providers
  • Due Diligence Consultants
  • Law Firms
  • Clinical Affairs and CRO Partners
  • Regulatory Affairs and Compliance Specialists

Top Reasons to Purchase

  • Review best practice updates of due diligence prior to, during, and after a sale to monetize a product in order to reduce time wasted and maximize efficiency
  • Mitigate risks by evaluating new rules and regulations due to COVID-19, specifically regarding the implications associated with remote due diligence practices
  • Learn how to facilitate global data sharing in a fair way that leverages the capability of information and makes manufacturing and distribution abilities more efficient
  • Understand digital health’s role in reshaping the future due diligence landscape – how virtual tools can affect decision making and data tracking more effective and ensure and compliance within regulatory guardrails
  • Discuss why organization and understanding of IP practices matters more than trying to reinvent the process

Thank you to our Sponsor

Fish & Richardson